Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis

Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO r...

Full description

Bibliographic Details
Main Authors: Marco Fiore, Aniello Alfieri, Sveva Di Franco, Maria Caterina Pace, Vittorio Simeon, Giulia Ingoglia, Andrea Cortegiani
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Antibiotics
Subjects:
carbapenem-resistant Enterobacteriaceae
multidrug resistance
β-lactamase inhibitors
anti-infective agents
bacteremia
ceftazidime-avibactam
Online Access:https://www.mdpi.com/2079-6382/9/7/388

Internet

https://www.mdpi.com/2079-6382/9/7/388

Similar Items